FOLFOX-HAIC plus regorafenib for the treatment of unresectable colorectal liver metastases refractory to first and second-line systemic chemotherapy
- 1Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Abstract
Background Hepatic arterial infusion chemotherapy (HAIC) is a potentially attractive locoregional therapy for patients with unresectable colorectal liver metastases (CRLM). This study aimed to evaluate the safety and efficacy of FOLFOX-HAIC plus regorafenib in the treatment of unresectable CRLM refractory to first and second-line systemic chemotherapy. Methods A total of 35 patients with unresectable CRLM who underwent FOLFOX-HAIC plus regorafenib between July 2020 and January 2023 were included in this retrospective study. The objective response rate (ORR), disease-controlled rate (DCR), progression-free survival (PFS), overall survival (OS) and adverse event were assessed. Factors affecting OS were analyzed. Results Kaplan–Meier curves showed that the median OS1 (measured from the time of diagnosis), OS2 (measured from the time of the first HAIC treatment) and PFS (measured from the time of the first HAIC treatment) were 29.0 (95%CI, 18.9–39.1) months, 21.0 (95%CI, 14.9–27.1) months and 13.0 (95%CI, 9.3–16.7) months, respectively. The ORRs at 3 months, 6 months and 12 months after HAIC were 57.1%, 45.7% and 22.9%, respectively, and the DCRs were 88.6%, 80.0% and 51.4%, respectively. No grade 5 adverse events (AEs) (death) were observed. Common Regorafenib-related AEs were hand-foot skin reaction (n = 18, 51.4%) and fatigue (n = 15, 42.9%). Common HAIC-related AEs were weight loss (n = 28, 80.0%), abdominal pain (n = 19, 54.3%) and nausea (n = 15, 42.9%). Conclusions FOLFOX-HAIC plus regorafenib might be beneficial and tolerable in the treatment of unresectable CRLM refractory to first and second-line systemic chemotherapy.
Related
- 270 AgenT-797, an allogeneic iNKT cell therapy, enables tumor-cell killing in a human organoid model of immune checkpoint inhibitor–refractory colorectal cancer liver metastases
- The Optimal Biological Therapy for Conversion in Patients with RAS-Wild-Type Colorectal Cancer and Unresectable Liver Metastases
- Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases
- Sotorasib plus panitumumab and 5-fluorouracil in first-line treatment of patients with unresectable KRAS G12C mutated colorectal cancer unfit for a doublet/triplet chemotherapy: ENGIC 01 – PRODIGE 107 – FFCD 2306 – COLOSOTO trial
- Efficacy and toxicities of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for unresectable pancreatic cancer: a systematic review and meta-analysis
BibTeX
@article{liu2026folfoxhaic,
title = {{FOLFOX-HAIC plus regorafenib for the treatment of unresectable colorectal liver metastases refractory to first and second-line systemic chemotherapy}},
author = {Jiacheng Liu and Songlin Song and Wei Yao and Yanqiao Ren and Yiming Liu and Chuansheng Zheng and Bin Liang},
journal = {BMC Cancer},
year = {2026},
month = jul,
doi = {10.1186/s12885-026-16545-7},
url = {https://doi.org/10.1186/s12885-026-16545-7},
note = {CC BY},
}
RIS
TY - JOUR
TI - FOLFOX-HAIC plus regorafenib for the treatment of unresectable colorectal liver metastases refractory to first and second-line systemic chemotherapy
AU - Jiacheng Liu
AU - Songlin Song
AU - Wei Yao
AU - Yanqiao Ren
AU - Yiming Liu
AU - Chuansheng Zheng
AU - Bin Liang
PY - 2026
DA - 2026/07/01
JO - BMC Cancer
DO - 10.1186/s12885-026-16545-7
UR - https://doi.org/10.1186/s12885-026-16545-7
AB - Background Hepatic arterial infusion chemotherapy (HAIC) is a potentially attractive locoregional therapy for patients with unresectable colorectal liver metastases (CRLM). This study aimed to evaluate the safety and efficacy of FOLFOX-HAIC plus regorafenib in the treatment of unresectable CRLM refractory to first and second-line systemic chemotherapy. Methods A total of 35 patients with unresectable CRLM who underwent FOLFOX-HAIC plus regorafenib between July 2020 and January 2023 were included in this retrospective study. The objective response rate (ORR), disease-controlled rate (DCR), progression-free survival (PFS), overall survival (OS) and adverse event were assessed. Factors affecting OS were analyzed. Results Kaplan–Meier curves showed that the median OS1 (measured from the time of diagnosis), OS2 (measured from the time of the first HAIC treatment) and PFS (measured from the time of the first HAIC treatment) were 29.0 (95%CI, 18.9–39.1) months, 21.0 (95%CI, 14.9–27.1) months and 13.0 (95%CI, 9.3–16.7) months, respectively. The ORRs at 3 months, 6 months and 12 months after HAIC were 57.1%, 45.7% and 22.9%, respectively, and the DCRs were 88.6%, 80.0% and 51.4%, respectively. No grade 5 adverse events (AEs) (death) were observed. Common Regorafenib-related AEs were hand-foot skin reaction (n = 18, 51.4%) and fatigue (n = 15, 42.9%). Common HAIC-related AEs were weight loss (n = 28, 80.0%), abdominal pain (n = 19, 54.3%) and nausea (n = 15, 42.9%). Conclusions FOLFOX-HAIC plus regorafenib might be beneficial and tolerable in the treatment of unresectable CRLM refractory to first and second-line systemic chemotherapy.
SN - 1471-2407
ER -